LLY vs NVO
LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies. NVO: A global healthcare leader specializing in innovative treatments for diabetes, obesity, and other serious chronic conditions.
Side-by-side fundamentals
| Metric | LLY | NVO | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $1,283.66 | $39.35 | |
| Market cap | $1.21T | $174.9B | |
| P/E as of 2026-10-20 | 43.09 | n/a | |
| PEG as of 2026-10-20, 3-year EPS CAGR to FY2025 | 0.87 | n/a | |
| Net margin FY2025, SEC XBRL | +31.7% | +33.1% | NVO higher |
| Gross margin FY2025, SEC XBRL | n/a | +81.0% | |
| Operating margin FY2025, SEC XBRL | n/a | +41.3% | |
| ROE FY2025, SEC XBRL | +77.8% | +52.8% | LLY higher |
| ROA FY2025, SEC XBRL | +18.4% | +18.9% | NVO higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 1.62 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +44.7% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +31.7% | +20.4% | LLY higher |
| Dividend yield as of 2026-09-03 | +0.6% | +2.7% | NVO higher |
| Dividend streak (yrs) SEC XBRL | 10 | n/a | |
| Beta as of 2026-09-03 | 0.54 | 0.82 | |
| 1-year return as of 2026-10-20 close | +58.7% | -29.4% | LLY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.